JPRN-UMIN000035616Recruiting未知
Prospective observational study of anti-PD-L1 antibody drug atezolizumab for non small cell lung cancer - Prospective study of atezolizumab
Second division, Depertment of Internal Medicine, Hamamatsu University School of Medicine0 sites100 target enrollmentStarted: January 28, 2019Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Patients with autoimmune diseases or recurrent autoimmune disease 2. Patient with interstitial pneumonia 3. Patients with serious complications 4. Patients with difficult-to-control central nervous lesions
Investigators
Similar Trials
Completed
Not Applicable
Prospective pilot study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously responded to anti-PD-1 antibodyadvanced non-small cell lung cancerJPRN-UMIN000031888Saitama medical university International medical Center20
Recruiting
Not Applicable
Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibodylung cancerJPRN-UMIN000033288Japanese Red Cross Medical Center30
Active, not recruiting
Phase 1
udwigEUCTR2015-005298-19-GBudwig Institute for Cancer Research Ltd.75
Recruiting
Phase 2
A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecular signaturebowlecancercolorectal carcinoma10017991NL-OMON49178Vall D'Hebron Institute of Oncology (VHIO)12
Active, not recruiting
Phase 1
Atezolizumab in combination with Beva in advanced CRC with MSI-like molecular signatureColorectal carcinomaMedDRA version: 20.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002001-19-ESVHIO58